A recent review suggests that screening men for prostate cancer through a blood test could potentially reduce deaths from the disease. The analysis, involving nearly 800,000 patients, indicates that using the prostate specific antigen (PSA) test for screening could be beneficial, although concerns about overdiagnosis and overtreatment persist. Cancer Research UK has also highlighted the limitations of the test’s effectiveness.
Prostate cancer is a common cancer in the UK, with over 64,000 new cases diagnosed each year. However, opinions on the efficacy of screening remain divided. Some experts argue that the PSA test, which measures a specific protein produced by the prostate, may lead to unnecessary treatments due to its unreliability in detecting cancer accurately.
The recent Cochrane review, which analyzed data from six trials involving a large number of patients, showed that screening could lower prostate cancer deaths from 16 to 14 per 1,000 men. This contrasts with a previous review in 2013 that found no significant reduction in mortality rates from screening.
The study did not assess the impact of screening on quality of life, such as potential complications from biopsies and treatment-related side effects. Dr. Juan Franco, the lead author, highlighted the challenge of overdiagnosis in prostate cancer cases, emphasizing the need for informed discussions between patients and healthcare providers before opting for screening.
While the findings support the idea of discussing PSA screening for men with a sufficient life expectancy, it is not a universal recommendation. Currently, the UK does not have a nationwide prostate cancer screening program, with PSA tests available on request for men over 50. The UK National Screening Committee advises screening every two years for men with specific genetic mutations associated with a higher risk of prostate cancer.
Dr. Ian Walker of Cancer Research UK acknowledged the potential benefits of screening in saving lives but cautioned about the risks of overdiagnosis and unnecessary treatment. The study underscores the complexity of balancing the benefits and harms of screening in making informed decisions.
A transformative trial funded by Prostate Cancer UK and the National Institute for Health and Care Research is exploring various screening methods, including genetic tests and quick MRI scans, to determine the most effective and cost-efficient approach for detecting prostate cancer in men.
